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Heck diversification of indole based substrates under aqueous 
conditions: from indoles to unprotected halo-tryptophans and 
halo-tryptophans in a natural and a new to nature natural product 
Cristina Pubill-Ulldemolins,[a,b] † Sunil V. Sharma,[a] † Christopher Cartmell,[a] † Jinlian Zhao,[a] Paco 
Cárdenas,[c] and Rebecca J. M. Goss*[a] 
Dedication  
Abstract: The blending of synthetic chemistry with biosynthetic 
processes provides a powerful approach to synthesis. Biosynthetic 
halogenation and synthetic cross-coupling have great potential to be 
used together, for small molecule generation, access to natural 
product analogues and as a tool for chemical biology. However to 
enable enhanced generality of this approach, further synthetic tools 
are needed. Though considerable research has been invested in the 
diversification of phenylalanine and tyrosine, functionalisation of 
tryptophans thorough cross-coupling has been largely neglected. 
Tryptophan is a key residue in many biologically active natural 
products and peptides; in proteins it is key to fluorescence, and 
dominates protein folding. To this end, we have explored the Heck 
cross-coupling of halo-indoles and halo-tryptophans in water, 
showing broad reaction scope. We have demonstrated the ability to 
use this methodology in the functionalisation of a new to nature 
brominated antibiotic (bromo-pacidamycin), as well as a marine 
sponge metabolite, barettin. 
Introduction 
Tryptophan is a key residue in many biologically active natural 
products peptides, and proteins.1,2 Its intrinsic fluorescence 
dominates the spectrophotometric properties of a given peptide 
or protein; it is a crucial residue for stabilising secondary and 
tertiary structure through intra and intermolecular interactions.3 
Tryptophan residues have been shown to play a central role in 
protein folding4 as well as being implicated in governing the 
function of many biologically important systems including 
mechanosensitive channels within the membrane.5 The 
possibility of functionalising tryptophan in order to modify this 
important residue both sterically and electronically would be 
exciting and potentially afford a means of interrogating, 
modulating and tuning the properties of peptides, proteins and 
natural products. 
 
Though considerable research has been carried out on selective 
modification of halogenated phenylalanines and tyrosines7 
through the application of cross-coupling chemistries, the 
functionalisation of tryptophan has, until recently, remained 
largely unexplored.6 One potential reason for this is the 
challenge that such metal mediated cross-coupling reactions 
present with tryptophan; indeed, tryptophan has been 
demonstrated to poison the Suzuki-Miyaura cross coupling of 
halo-indoles.8 This may be attributed to the aminoacid 
coordinating to the palladium catalyst.9 Notably, esterification of 
the carboxylate and acylation of the primary amine reduces 
reaction poisoning, however even this species is not fully 
innocent and its incorporation in a reaction is still seen to impact 
upon conversion.8 
 
In recent years, series of studies enabling the cross-coupling of 
halo-tryptophans through application of Suzuki-Miyaura and 
Sonogashira chemistries in aqueous media have been 
reported.6-8 Combination of these chemistries with enzymatic 
halogenation has been used powerfully for selective C-H 
activation and diversification of small molecules10 The 
application of Heck cross-coupling would provide a valuable 
addition to this growing portfolio of reactions for tryptophan 
functionalisation, enabling the potential for extension of 
conjugation and tuning of electronic and fluorescence properties 
as well as the opportunity to potentially modulate conformations 
of small molecules, peptides and proteins.  
 
Heck cross coupling methodologies have been effectively 
applied to series of other biomolecules including nucleosides,11 
nucleotides and nucleoside triphosphates.12 However, there are 
very few studies reported of the utilisation of Heck 
methodologies for the modification of amino acids, and peptides, 
mostly utilising highly activated (iodo or triflate) substrates. 
These include modification of N and C protected 3,5-di-iodo-L-
tyrosine, modulating and extending its conjugation and enabling 
its fluorescence properties to be tuned, and diversification of N 
and C protected L-tyrosine para-triflate,13 and selective 
modification of 4-iodo-L-phenylalanine within a small protein, 
using Mizoroki-Heck conditions.14 
 
Whilst this manuscript was being prepared, the first Mizroki-Heck 
coupling of a halo-tryptophan was reported. In this study free, 
unprotected 7-bromo-tryptophan was derivatised with 6 different 
styrenes.15 Excitingly, as observed with the Suzuki-Miyaura 
cross-coupling of tryptophan,6a,8 these tryptophan-7-styrene 
products were shown to be fluorogenic, thus again opening up 
the way for fluorescence modulation of halo-tryptophans. There 
is considerable potential for the development of Heck 
methodologies for the functionalisation of free and biomolecule 
embedded halo-tryptophans. Herein, we report our exploration 
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of the systematic application of the Heck reaction first to halo-
indoles, then to free and unprotected halo-tryptophans. We then 
move on to challenge the developed methodology, applying it to 
unprotected and complex natural product, barettin and new to 
nature bromo-pacidamycin with a range of aliphatic and 
aromatic alkenes.  
 
 
Scheme 1. Heck cross-coupling under aqueous conditions applied to 
biomolecules: All relevant prior work is outlined along with work within this 
study. (A) Shaughnessy’s initial aqueous Heck cross-coupling,16 (B) Tagging 
of 4-iodo-L-phenylalanine within a small protein.14 (C) Heck modification of 
iodinated nucleoside triphosphates12,13 (D) Reported Heck modification of 7-
bromo-tryptophan with styrenes.15 (E), (F) Heck modification of a series of 
indoles and tryptophans respectively, (G) and (H) Heck modification of the 
antibiotics barettin and pacidamycin respectively. 
 
Results and Discussion 
Moore and Shaughnessy first exemplified the use of aqueous 
phase Heck coupling of aryl bromides using the sterically 
demanding tri-(4,6-dimethyl-3-sulphonatophenyl)-phosphine 
trisodium salt (TXPTS) as ligand to enable water solubilisation of 
the Pd(OAc)2. Their mild aqueous conditions, employing Na2CO3 
as base enabled modification of aryl iodides and bromides in 
high yield (79-94%).16 Starting with their reported conditions, we 
explored whether these could be utilised to enable Heck 
modification of reactive 5-iodo-indole 1 with acrylic acid 2. 
Conventional heating at 80 ºC for 2 hours was found to give a 
conversions of 18%, whereas by heating for longer periods 
using Na2PdCl4-TXPTS catalyst, it was possible to increase 
conversion to 51% (Table 1).  
 
  
Table 1. Initial Heck cross-coupling conditions explored for 5-I-indole with 
acrylic acid.  
 
Entry X  Pd/Ligand Time Conv.%[a],[b]  Yield
 %[c] 
1 5-I Pd(OAc)2/TXPTS 2h 18 - 
2 5-I Pd(OAc)2/TXPTS 18h 32 - 
3 5-I Na2PdCl4/TXPTS 18h 51 43 
Reaction conditions: (a) 5-I-indole (0.1 mmol), acrylic acid (1.5 eq, 0.15 
mmol), Pd salt (2.5 mol%), TXPTS (6.25 mol%), Na2CO3 (2.0 eq, 0.2 
mmol), CH3CN/H2O (1:1, 1 mL), conventional heating, reflux, solids and 
solvents purged with argon. (b) Based on ratio of starting material 
aromatic peak at dH 6.40 ppm compared to product aromatic peak at dH 
6.50 ppm in CD3OD. (c) Isolated yields are reported after flash 
chromatography. 
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In order to improve the reaction we next explored the impact of 
varying the catalyst, (investigating water soluble Na2PdCl4) in 
combination with exploring the application of the sterically more 
demanding and electron-rich SSPhos ligand, designed by 
Buchwald.17 Microwave heating was also explored (Table 2). 
 
  
Table 2. Optimization of the reaction conditions. 
 
 
Entry X Pd/Ligand Time Conv.%[a],[b] Yield 
%[c] 
1 5-I 1 Pd(OAc)2/TXPTS Reflux, 
18h 
78 67 
2 5-I 1 Pd(OAc)2/sSPhos Reflux, 
18h 
85 73 
3 5-I 1 Na2PdCl4/ sSPhos Reflux, 
18h 
97 86 
4 5-I 1 Na2PdCl4/ sSPhos MW, 1h >99% 90 
5 5-I 1 Na2PdCl4/ none MW, 1h >99% 89 
6 5-Br 4 Na2PdCl4/ none MW, 1h 48% 36 
7 5-Br 4 Na2PdCl4/ TXPTS MW, 1h 77% 65 
8 5-Br 4 Na2PdCl4/ sSPhos MW, 1h >99% 94 
 
Reaction conditions: (a) 5-X-indole (0.1 mmol), acrylic acid (1.5 eq, 0.15 
mmol), Pd catalyst (5 mol%), ligand (12.5 mol%), Na2CO3 (4 eq, 0.4 mmol), 
CH3CN/H2O (1:1, 1 mL), conventional or microwave heating, solids and 
solvents purged with argon. (b) Based on ratio of starting material aromatic 
peak at dH 6.40 ppm compared to product aromatic peak at dH 6.50 ppm in 
CD3OD. (c) Isolated yields are reported after flash chromatography. 
  
 
These studies revealed that by using SSPhos in place of TXPTS 
a modest increase in conversion of 5-iodo-indole 1 could be 
achieved (78%-85% Table 2 entries 1 and 2), significant 
increase in conversion (97%) could be seen upon replacing 
Pd(OAc)2 with the water soluble Na2PdCl4 catalyst (Table 2, 
entry 3). By replacing conventional heating with microwave 
heating, >99% conversion could be achieved after only one hour. 
Notably, for 5-I-indole 1, it was possible to achieve almost 
quantitative conversion, using microwave heating, in the 
absence of additional ligand (Table 2, entry 5). Next we set out 
to explore the Heck modification of the less reactive 5-Br-indole 
4; here we observed conversions to be far more modest in the 
absence of any ligand, however utilisation of SSPhos again 
enabled to obtain almost quantitative conversions (Table 2, entry 
8). 
 
With these initial conditions in hand, we next set out to explore 
whether we could proceed past acrylic acid 2 as the coupling 
partner. The conditions that we had developed showed good 
applicability enabling the Heck modification of both 5-iodo 1 and 
5-bromo-indole 4 to proceed almost quantitatively with a range 
of different alkene cross-coupling partners (Table 3). 
  
  
Table 3. Heck cross-coupling of 5-X-Indoles with different alkenes using 
Na2PdCl4/sSPhos as catalytic system. 
 
 
Entry X R Product Conv.%[a],[b] Yield %
[c] 
1 5-I 1 CO2Et 8 13 >99 60[d] 
2 5-I 1 COOH 2 3 >99 92 
3 7-I 5 COOH 2 14 >99 91 
4 5-I 1 COMe 9 15 >99 85 
5 5-I 1 CN 10 16 >99 75 
6 5-I 1 Ph 11 17 33 - 
7 5-Br 4 CO2Et 12 13 >99 71[d] 
8 5-Br 4 COOH 2 3 >99 94 
9 6-Br 6 COOH 2 18 >99 83 
10 7-Br 7 COOH 2 14 >99 89 
Reaction conditions: (a) 5-X-indole (0.1 mmol), alkene (1.5 eq, 0.15 mmol)  
Na2PdCl4 (5 mol%), sSPhos (15 mol%), Na2CO3 (4.0 eq, 0.4 mmol), 
CH3CN/H2O (1:1, 1 mL), MW heating used, solids and solvents purged with 
argon. (b) Based on ratio of starting material aromatic peak at dH 6.40 ppm 
compared to product aromatic peak at dH 6.40 ppm in CD3OD (c) Isolated 
yields are reported after flash chromatography, (d) desired product formed 
alongside acrylic acid derivative due to hydrolysis of the ethyl ester under 
basic conditions. Yields are reported for the ethyl acrylate product only. 
  
The only exception to this rule was styrene 11 (Table 3, entry 6) 
because of the reduced reactivity of this species arising due to 
the electron rich nature of the alkene. Also, for this reason, 
unactivated 1-octene and cyclohexene gave no conversion 
under the same reaction conditions. From NMR characterisation 
of the products it may be seen that all Heck couplings 
progressed with a high level of stereoselectivity to generate only 
the E-isomers. The trans-relation of the double bonds was 
established on the basis of the coupling constant for the vinylic 
protons in the 1H NMR spectra (J ~16 Hz, see SI). 
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Having achieved a system that would work well for the 
functionalisation of iodo- and bromo-indoles 1 and 4, we next set 
out to explore whether it might be possible to extend this 
methodology further to the aqueous cross-coupling of the far 
more challenging free, unprotected halo-tryptophans. 
 
 
 
  
Table 4. Heck cross-coupling on unprotected halo-tryptophans with acrylic 
acid. 
 
 
En
try 
X Prod Ligand t (h) T (ºC) Conv.%
[a],[b] 
Yield 
%[c] 
1 5-Br 19 25 SSPhos 1 80 <1 - 
2 5-Br 19 25 “ 2 100 <1 - 
3 7-I 20 26 TPPTS 1 90 65 - 
4 7-I 20 26 TPPTS 2 90 >99 93 
5 7-I 20 26 TXPTS 1 80 24 - 
6 7-I 20 26 TXPTS 1 90 >99 93 
7 7-Br 21 26 TPPTS 2 90 47 - 
8 7-Br 21 26 TXPTS 1 90 >99 87 
9 5-Br 19 25 TPPTS 1 90 >99 95 
10 6-Br 22 27 TPPTS 1 90 >99 -[d] 
11 4-Br 23 28 TXPTS 1 90 <1 - 
12 5-Cl 24 25 TXPTS 1      90      <1 - 
Reaction Conditions: (a) Tryptophan (0.05 mmol, 1.0 eq), acrylic acid (0.075 
mmol, 1.5 eq), Na2PdCl4 (10 mol%), Ligand (23 mol%), Na2CO3 (4 eq), 
water/acetonitrile (3:1, 1 mL, degassed), microwave heating, 90 °C, 1 h. (b) 
Based on NMR ratios of starting material to product material in CD3OD. (c) 
Products purified by reverse phase chromatography with a MeOH/H2O 
gradient (d) Product could not be isolated pure due to potential degradation 
through reverse phase column chromatography. 
 
  
 
Halo-tryptophans may be readily accessed through a simple 
one-step biotransformation using tryptophan synthase,18,19 or 
through a 4-5 step chemical synthesis.20 Challenges that need to 
be addressed to render Heck cross-coupling of free halo-
tryptophans useful are their poor solubility and their propensity 
to chelate to and deactivate the palladium catalyst.9  
Utilisation of our previous conditions that had been optimised for 
the aqueous Heck cross-coupling of halo-indoles with acrylic 
acid resulted in almost no observable conversion of 5-bromo-
tryptophan 19 even at 100 °C (Table 4 entries 1 and 2), we 
therefore returned to exploration of both TXPTS and TPPTS as 
water soluble ligands with the highly reactive 7-iodo-tryptophan 
20. By doubling both the amount of catalyst and ligand, it was 
possible to achieve almost quantitative conversion using either 
TPPTS or TXPTS when heated to 90 °C, though with TPPTS an 
extended reaction time of 2h was required (Table 4 entries 3-6). 
Applying these conditions, using TPPTS to the less reactive 7-Br 
tryptophan 21, a conversion of only 47% is observed (Table 4 
entry 7). However by switching to the more sterically demanding 
TXPTS ligand, almost quantitative conversion was achieved 
(Table 4 entry 8). As the 5 and 6 halo-tryptophans are more 
reactive than the 4 and 7-counterparts, the sterically less 
demanding TPPTS was found suitable to afford almost 
quantitative conversion of 5-bromo and 6-bromo-tryptophan 19 
and 22 (Table 4 entries 9 and 10). Importantly, as seen for the 
halo-indoles the reaction is highly stereoselective towards the E 
product (See SI).  
 
Observed Limitations in Reactivity: The 4-bromo-tryptophan 
23 is highly unreactive and even using TXPTS as ligand, only a 
small trace of product may be perceived from the reaction. 
Curiously, the sole application of Heck cross-coupling to 
tryptophan reported in the literature is the functionalisation of 4-
bromo-tryptophan 23 in the synthesis of clavicipitic acid 
(reported as 91% conversion using conventional heating);15 we 
have been unable to reproduce this conversion using either the 
system that we have developed or their conditions with alkene 
1,1-dimethylallyl alcohol, TPPTS, Pd(OAc)2 and NaOH as base. 
Forcing the reaction by MW heating to 130 °C for 2h we were 
finally able to observe conversion of ~15%. 
 
The less reactive aryl chloride, as a component of either the 
simple indole system or within tryptophan is also recalcitrant to 
Heck modification under all conditions that we have explored. 
However, we demonstrate that following protection of the 
primary amine (using N-Boc-4-Br-tryptophan), Heck coupling at 
position 4 can be achieved using our conditions. A similar trend 
was observed for reactivity of free versus protected 2-bromo or 
4-bromophenylalanine. These observations strongly indicate 
influence of free α-amino group on the Pd-catalysed cross 
coupling of 4-halo-tryptophans (see SI). 
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Na2Cl4Pd (10 mol%)
TXPTS (23 mol%)
4 eq of Na2CO3
CH3CN:H2O (1:3) 
(Degassed)
90ºC (MW), 2h
N
H
N
H
 2.0 eq
NH2
COOHCOOH
NH2
X
5
7
5
7
X: 5-Br 19
R R
R: EDG, EWG7-Br 21
5BrW: 65% (4:1) E/Z  29
7BrW: 72%  E 30
N
H
NH2
COOH
R
N
H
NH2
COOH
N
5BrW: 85% (3:1) E/Z  40
7BrW: 71% E    41
F
CN
Me
NH2
5BrW: 90% 35
7BrW: 80% E 36
5BrW: 91% E 38
7BrW: 89%  39
5BrW: 51 (5:1) E/Z  31
7BrW: 62 (7:1) E/Z  32
5BrW: 65% (2:1) E/Z  33
7BrW: 55% (8:1) E/Z  34
H
meta-F 7BrW: 92% E 37
 
Scheme 2. Scope of alkene partner with styrene derivatives. The impact of 
modification of sterics and electronics is explored. 
With conditions established that would enable the facile 
conversion of 5, 6 and 7 iodo and bromo-tryptophans, we next 
set out to explore the impact of sterics and electronic and 
solubility of the cross-coupling partners. Through this we could 
observe that progression from acrylic acid to bulkier aromatic 
substrates could be successfully achieved. Trend in coupling 
efficiency seems to follow electronics rather than substrate 
solubility. It is clearly evident from the results that electron 
donating substituents (i.e. Me or amino) decrease the reactivity 
of alkene resulting in lower yields (51 – 65%, compounds 31-34). 
On the contrary, electron withdrawing fluoro or nitrile derivatives 
gave significantly higher yields (80-92%, compounds 35-39), 
and reactions also worked well with heterocyclic alkene 
substrates such as 4-vinylpyridine (compounds 40, 41). 
 
From NMR characterisation of the products, it may be seen that 
for the 5-bromo and 5-iodo-tryptophan an almost equal mixture 
of the E and Z isomer are generated, whereas for the 7-bromo 
and 7-iodo-tryptophans the E stereoisomer predominate (see SI).  
The selective diversification of natural products is an important 
area. Such work can enable systematic modification and 
optimisation of a bioactive molecule’s properties, or enable 
tagging and tracking, or be utilised in target identity. As proof of 
principle we next set out to explore whether Heck cross-coupling 
might be applied to the cross-coupling of tryptophan residues 
within two test-bed natural products. The sponge halo-
metabolite barettin, a brominated a diketopiperazine-type cyclic 
dipeptide (42), is known for its roles in chemical defence against 
predators, antifouling activity and binding to serotonergic 5-HT 
receptors.21 Heck modulation could potentially be explored to 
enable analogue generation to gain greater understanding of the 
molecule’s structure activity relationship. Furthermore, Heck 
tagging impacts upon the fluorescence of halo-
indoles/tryptophans, such a strategy could potentially be applied 
to enable the tissues in which it is generated to be seen, as well 
as enabling tracking of the metabolite and potentially revealing 
its targets. 
HN
NH
O
O
HN
Br
N
H
NH2
NH
HN
NH
O
O
HN N
H
NH2
NH
F
>99%, 21%
(5 eq)
Na2Cl4Pd (10 mol%)
TXPTS (23 mol%)
Na2CO3 (4 eq)
H2O:CH3CN (1:1)
(degassed)
90ºC, MW, 2h
F
42
43
 
Scheme 3. Application of Heck to the diversification of the marine natural 
product, barettin. Reaction carried out on 2mg. 
Within barettin the primary amine and carboxylate of tryptophan, 
that would usually add challenge to cross-coupling reaction 
progression, are masked as amides within a diketopiperazine. 
Many marine metabolites are highly lipophilic, limiting their 
diffusion from their producer, enabling the producer to retain the 
metabolites. In order to solubilise barettin a higher ratio of 
acetonitrile was required. Once solubilised, the reaction 
proceeded well affording product 43. 
 
Pacidamycin, belonging to the class of uridyl peptide antibiotics, 
represents a potentially more challenging substrate, comprised 
of a pseudo-peptide backbone attached via an exocyclic 
enamide to a modified uridine. We had previously demonstrated 
the first out of context use of a halogenase, by introducing the 
gene encoding tryptophan-7-halogenase prnA in Streptomyces 
coeruleorubidis (RG-5059) in order to generate Cl-
pacidamycin.6a We have successfully utilized a synthetic 
biological approach to generate an engineered strain (S. 
coelicolor M1154, named RG1104) capable of generating new to 
nature bromometabolites, Br-pacidamycin D (44) and performing 
in culture Suzuki-Miyaura derivatisation to gain access to new 
aryl-pacidamycin D analogue.8  
 
In this study, we employed the same strain in ISP2 medium for 
production and isolation of Br-pacidamycin D and cultures were 
grown for a total of 7-8 days. Production of new to nature Br-
pacidamycin D along with wild type pacidamycin D was detected 
by LC-HRMS analysis. Isolation of the target compounds was 
effected by using the following sequence of purification steps: 
solid phase extraction (XAD-16 resin), enrichment of 
pacidamycins using ion exchange chromatography (HiTrap SP-
FF columns) and finally reverse phase purification (semi-
preparative HPLC) (see SI for details).  
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TXPTS (23 mol%)
Na2CO3 (4 eq)
H2O:CH3CN (3:1)
(degassed)
90ºC, MW, 2h
F
Engineered Streptomyces coelicolor M1154,(RG1104 ) strain containing
pacidamycin biosynthetic genes and prnA (halogenase)
Synthetic biology
New to nature Br-pacidamycin D (44)
New alkene functionalised pacidamycin analogue (45)  
Scheme 4. Application of Heck to the diversification of pacidamycin 
In this manner, reasonably pure samples of wild type 
pacidamycin D (~1 mg) and Br-pacidamycin D (~0.5 mg) were 
isolated. Although limited amounts of isolated material in hand, 
we could perform partial NMR analysis on these samples. While 
1H NMR on pacidamycin D was satisfactory, peak broadening 
was observed for brominated analogue. Gratifyingly, some key 
difference were noted by careful comparison of the HSQC-NMR 
(see SI), notably 1H and 13C peak at 7.35 and 110.7 ppm for 
pacidamycin D was absent in the HSQC spectrum of Br-
pacidamycin D-thus indicating substitution in desired position. 
LC-HRMS2 analyses showed desired isotope pattern (m/z 790, 
792 for 79Br, 81Br respectively) and satisfactory MS2 
fragmentation was obtained (see SI). 
 
In order to enable the modification of bromo-pacidamycin 
through application of Heck chemistry we first explored reactions 
on crude extracts containing very low concentrations of this 
bromometabolite. Using our optimum conditions developed for 
Br-tryptophan, we were pleased to see full conversion of Br-
pacidamycin D from crude extract and LC-HRMS2 analyses 
confirmed formation of the desired cross-coupling product. Next 
we carried out the Heck coupling on a purified sample of Br-
pacidamycin D (~0.5 mg). Although the cross-coupling was 
successful as confirmed by LC-HRMS2 analysis (LC-HRMS2 
product m/z C40H47FN9O10+ [M+H]+: 832.3424; found: 832.3422), 
the corresponding product 45 could not be successfully isolated 
on this very small scale. These results indicated that our 
methodology have the potential to be utilised for micro-scale 
tagging or functionalisation of brominated metabolites, even as 
components of a complex extract without the need for prior 
application of purification or protection strategies. 
 
Conclusions 
We have developed conditions enabling Heck cross- coupling of 
iodo and bromo-indoles, and free unprotected 5, 6 and 7-bromo-
tryptophan and 7-iodo-tryptophan, showing the reaction to be 
very high yielding. Near quantitative cross-coupling of iodo and 
bromo-indoles can be achieved in the absence of ligand, 
however to enable comparable conversions of halo-tryptophans, 
a water-soluble ligand is required, and we found that TXPTS and 
TPPTS could be used effectively. Whilst high conversions could 
be achieved for 5, 6, and 7-iodo and bromo-indoles and 
tryptophans, exploration of limitation of scope revealed the less 
reactive aryl chlorides to be recalcitrant to cross-coupling under 
our conditions, 4-halo-tryptophan also proved demanding. It may 
be noted that efficiency of the reaction is impacted by both 
substrate reactivity and solubility. 
 
We have demonstrated the ability to carry out Heck modification 
of halo-tryptophan with a wide range of alkenyl cross-coupling 
partners. Introducing this chemistry to more sensitive and 
complex systems in which halo-tryptophans are embedded, we 
have usaed synthetic biology to engineer the production of the 
new to nature halometabolite, bromo-pacidamycin, and have 
demonstrated the selective modification of this polar antibiotic, 
even as a component of a complex broth extract. We have also 
demonstrated the application of these conditions to the 
modification of barettin a natural and lipophilic metabolite 
obtained from a sponge. 
 
The fairly mild aqueous condition, the high conversions and 
flexibility of the substrate scope, make the Heck reaction a 
useful tool for application to chemical biology and molecule 
tagging as well as to GenoChemetic approaches to natural 
product analogue generation. Tryptophan is an important 
residue in natural products, peptides and proteins with a key role 
in folding, function and fluorescence. The extension and 
modulation of the conjugation enabled by Heck cross-coupling 
with series of alkene partners provides the potential for tuning 
the conformation and modulating fluorescence properties. 
Experimental Section 
Proton (1H), and carbon NMR (13C) were recorded on either a Bruker 
Ascend HD700 (700 MHz), Bruker Ascend 500 (500 MHz) or a Bruker 
400 UltraShield (400 MHz) spectrometer. The NMR experiments were 
carried out in deuterated chloroform (CDCl3) deuterated water (D2O), 
deuterated DMSO (DMSO-d6) or deuterated methanol (d4-MeOH). The 
chemical shifts (d) are quoted in parts per million (ppm). Using a DEPTQ 
sequence or an HSQC experiment with multiplicity editing, the 13C NMR 
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signals were identified to CH3, CH2, CH and C. Coupling constants are 
reported in Hertz (Hz).  
High and low resolution mass spectra that were recorded at the 
University of St Andrews on an Orbitrap VELOS pro. Freeze drying was 
carried out on a Scanvac CoolSafeTM freeze dryer. Microwave reactions 
were effected in sealed vials using a Biotage Initiator+ microwave reactor. 
UPLC analysis was acquired on a Waters Acquity H-Class UPLC system 
fitted with a Waters Acquity UPLC BEH C18 column (1.7 µm, 2.1×50 
mm) or Phenomenex Kinetex Phenyl-hexyl column (2.1 µm, 2.1×75 mm).  
Flash chromatography was performed using Davisil silica gel LC60A (40-
63 micron). Thin layer chromatography (TLC) was executed using 
aluminium sheets of silica gel 60 F254 and was visualised under a 
Mineralight model UVGL-58 lamp (254 nm). The plates were developed 
with ninhydrin in acetone or basic potassium permanganate solutions. 
Purification of unprotected tryptophan derivatives and peptides was 
carried out on a Biotage Isolera Four using reverse-phase SNAP C18 12 
g column cartridges. The purification was carried out using water (solvent 
A) and methanol/acetonitrile (solvent B) using the following gradient: 0-
1.5 min (5% B), 1.5-3.0 min (5% to 15% B), 3.0-5.0 min (15% B), 5.0-
15.0 min (15% to 95% B), 15.0-18.0 min (95% B), 18.0-20.0 min (95%-
5% B), 20.0-25.0 min (5% B) at a flow rate of 12-15 mL/min.  
Preparative RP-HPLC purification was performed using a Gilson 322 
pump, 151 UV/VIS detector and 233XL fraction collector, using a 
Phenomenex Luna C18 (5 micron, 250 ×21.2 mm) with UV detection at 
234 nm. Elution was carried out using a shallow linear gradient with 
starting conditions 95% solvent A (0.1% formic acid in MQ water) to 5% 
solvent B (ACN) to 40% solvent B over 40 mins. 
Experimental details and characterisation data N-Boc protection of 4-Br-
(S)-tryptophan, it’s subsequent Heck coupling and deprotection affording 
compound 28, as well as Heck reaction for N-Boc-4-Br-phenylalanine 
and N-Boc-2-Br-phenylalanine are presented in SI. 
General protocol for Heck Cross-coupling of halo-indoles with 
alkenes in aqueous conditions. In a 10 mL pear-shape flask or 0.5-2 
mL MW vial, sodium tetrachloropalladate (1.6 mg, 5 µmol, 5 mol%), 
sulfonated SPhos (6.6 mg, 12.5 µmol, 12.5 mol%) were purged with 
nitrogen and stirred at rt for 15 min after adding 1 mL of degassed 
water/acetonitrile (1:1) mixture. Then, appropriate halo-indole (0.1 mmol, 
1.0 eq) is added together with Na2CO3 (22 mg, 0.2 mmol, 2eq) followed 
by addition of the alkene (0.15 mmol, 1.5 eq). The reaction mixture was 
heated at 80 °C (MW or conventional heating) for the required period of 
time. The reaction mixture was cooled to r.t. and diluted with 5 mL of a 
saturated solution of NaHCO3. The aqueous layer was extracted with 
ethyl acetate (3×10 mL). The combined organic layers were dried over 
anhydrous Na2SO4 and the solvent removed in vacuo. Purification by 
column chromatography using silica gel (Hexanes/ethyl acetate 4:1). 
Characterisation data for isolated indole-Heck products (3, 13-18) are 
presented in SI. 
General protocol for Heck Cross-coupling of unprotected halo-
tryptophans with acrylic acid in aqueous conditions. In a 0.5-2 mL 
MW vial, sodium tetrachloropalladate (1.5 mg, 5 µmol, 10 mol%), with 
appropriate ligand (TPPTS 6.5 mg or TXPTS: 7.0 mg, 11.5 µmol, 23 
mol%) were purged with argon and stirred at rt for 15 min after adding 1 
mL of degassed water/acetonitrile (3:1) mixture, 1 mL. Then, the 
corresponding halo-tryptophan (0.05 mmol) was added together with 
Na2CO3 (22 mg, 0.2 mmol, 4 eq.) followed by addition of the acrylic acid 
(6 µl, 0.075 mmol, 1.5 eq). The vial was closed and the reaction mixture 
was stirred and heated at 90 °C (MW) for 1 hour. After completion, the 
reaction was cooled down to rt was diluted with water (2 ml) and acidified 
(pH ~2-3) using 0.1 M HCl. Solvent was removed under reduced 
pressure. The desired product was obtained by purification using 
gradient reversed phase chromatography (C18, 12 g) eluting with MeOH-
water (5-95% gradient). 
(E)-3-(3-((S)-2-amino-2-carboxyethyl)-1H-indol-5-yl)acrylic acid (25) 
Using TPPTS as a ligand, the above procedure afforded 13 mg (95% 
from 5-Br-tryptophan) of the title product as a white solid.  
1H NMR (400 MHz, MeOD) δ 8.01 (s, 1H, ArH), 7.84 (d, J = 15.9 Hz, 1H, 
CH=CH-Ar), 7.51 – 7.33 (m, 2H, ArH), 7.25 (s, 1H, ArH), 6.46 (d, J = 15.9 
Hz, 1H, CH=CH-Ar), 3.89 (dd, J = 9.1, 4.1 Hz, 1H, CH), 3.52 (dd, J = 
15.0, 4.5 Hz, 1H, CHAHB), 3.19 (dd, J = 15.3, 9.1 Hz, 1H, CHAHB). 13C 
NMR (126 MHz, DMSO-d6) δ 170.1 (CO), 168.3 (CO-CH=CH), 146.1 
(CO-CH=CH-Ar), 137.6 (C), 127.7 (C), 125.6 (CH), 124.9 (C), 121.1 (CH), 
120.3 (CH), 115.3 (CO-CH=CH-Ar), 111.8 (CH), 110.6 (C), 54.7 (CH), 
26.9 (CH2). HRMS (FTMS -p NSI) C14H13N2O4 [M - H]- calculated for 
273.0881, found 273.0880. 
(E)-3-(3-((S)-2-amino-2-carboxyethyl)-1H-indol-7-yl)acrylic acid (26) 
The above procedure afforded 11.9 mg (87% from 7-Br-tryptophan) and 
12.7 mg (93% from 7-I-tryptophan) of the desired product as a white solid.  
1H NMR (400 MHz, MeOD) δ 8.10 (d, J = 16.0 Hz, 1H, CH=CH-Ar), 7.80 
(d, J = 7.5 Hz, 1H, ArH), 7.47 (d, J = 7.4 Hz, 1H, ArH), 7.29 (s, 1H, ArH), 
7.13 (t, J = 7.7 Hz, 1H, ArH), 6.57 (d, J = 16.0 Hz, 1H, CH=CH-Ar), 3.87 
(dd, J = 9.1, 4.1 Hz, 1H, CH), 3.52 (dd, J = 15.3, 4.0 Hz, 1H, CHAHB), 
3.20 (dd, J = 15.3, 9.1 Hz, 1H, CHAHB). 13C NMR (101 MHz, MeOD) δ 
174.2 (CO), 171.0 (CO-CH=CH), 142.2 (CO-CH=CH-Ar), 136.7 (C), 
129.8 (C), 126.2 (CH), 122.5 (CH), 122.1 (CH), 120.6 (CH), 119.9 (C), 
119.3(CO-CH=CH-Ar), 110.6 (C), 56.6 (CH), 28.2 (CH2). HRMS (FTMS -
p NSI) C14H13N2O4 [M - H]- calculated for 273.0881, found 273.0884. 
(E)-3-(3-((S)-2-amino-2-carboxyethyl)-1H-indol-6-yl)acrylic acid (27) 
Using TPPTS as a ligand, after completion, the reaction was cooled 
down to rt was diluted with water (2 ml) and acidified (pH ~2-3) using 0.1 
M HCl. Solvent was removed under reduced pressure. 1NMR analysis 
showed clearly full conversion (>99%) towards the title product. 
Unfortunately, our attempts to purify the product by reverse phase 
chromatography failed as the product seems to degrade through C18 
even at neutral pH (~7). 1H NMR extracted from the mixture of final 
product and partially oxidized TXPTS.  
1H NMR (500 MHz, MeOD) δ 7.78 – 7.75 (m, 2H, overlapping ArH, 
CH=C), 7.60 (s, 1H, ArH), 7.38 (dd, J = 8.4, 1.4 Hz, 1H, ArH), 7.33 (s, 1H, 
ArH), 6.46 (d, J = 15.9 Hz, 1H, C=CH), 3.87 (dd, J = 9.1, 4.2 Hz, 1H, CH), 
3.52 (dd, J = 15.2, 4.1 Hz,1H, CHAHB), 3.20 (dd, J = 15.2, 9.1 Hz, 1H, 
CHAHB). 13C NMR (126 MHz, MeOD) δ 172.6 (CO), 169.8 (CO)*, 146.5 
(CH), 137.0 (C), 129.0 (C), 128.2 (C), 126.3 (CH), 118.4 (CH), 118.5 
(CH), 115.5 (CH), 112.2 (CH), 108.7 (C), 55.3 (CH), 26.8 (CH2).* 
Identified from HMBC spectrum. HRMS (FTMS -p NSI) C14H13N2O4 [M - 
H]- calculated for 273.0881, found 273.0871. 
General protocol for Heck Cross-coupling of unprotected halo-
tryptophans with styrene derivatives in aqueous conditions. 
In a 0.5-2 mL MW vial, sodium tetrachloropalladate (1.5 mg, 10 µmol, 10 
mol%), TXPTS (7.0 mg, 23 µmol, 23 mol%) were purged with argon and 
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stirred at r.t. for 15 min after adding 1 mL of degassed water/acetonitrile 
(3:1) mixture. Then, appropriate halo-tryptophan (0.05 mmol) was added 
together with Na2CO3 (22 mg, 0.2 mmol, 4 eq.) followed by addition of 
the styrene derivative coupling partner (0.075 mmol, 1.5 eq). The vial 
was closed and the reaction mixture was stirred and heated at 90 °C 
(MW) for 2 hours. After completion, the reaction cooled down to r.t. was 
diluted with water (2 ml) and extracted with diethyl ether (3×2 ml) to 
remove the excess of the alkene coupling partner. The aqueous layer 
was acidified (pH ~2-3) using 0.1 M HCl. Solvent was removed under 
reduced pressure. The desired product was obtained by purification 
using gradient reversed phase chromatography (C-18, 12 g) eluting with 
water-MeOH (5-95% gradient). 
(S)-2-amino-3-(5-styryl-1H-indol-3-yl)propanoic acid (29) 
The above procedure afforded 10.9 mg (72% from 5-Br-tryptophan) of 
the desired product as a white solid. LC-MS analysis indicated the 
presence of separable E and Z isomers (4:1). 
1H NMR (500 MHz, MeOD) δ 7.89 (s, 1H, CH), 7.58-7.50 (m, 2H, 
CH=CH), 7.43 (dd, J = 8.5, 1.4 Hz, 1H, ArH), 7.39 – 7.27 (m, 4H, ArH), 
7.23 – 7.11 (m, 3H, ArH), 3.95 (dd, J = 9.4, 4.3 Hz, 1H, CH), 3.55 (dd, J = 
15.6, 4.3 Hz, 1H, CHAHB), 3.20 (dd, J = 15.6, 9.4 Hz, 1H, CHAHB). 13C 
NMR (126 MHz, MeOD) δ 174.4 (CO), 139.6 (C), 138.3 (C), 131.3 (CH), 
130.3 (C), 129.8 (2CH), 128.8 (C), 127.8 (CH), 127.1 (2CH), 126.6 (CH), 
125.9 (CH), 121.6 (CH), 118.2 (CH), 112.7 (CH), 110.1 (C), 56.7 (CH), 
28.5 (CH2). HRMS (FTMS -p NSI) C19H19N2O2 [M - H]- calculated for 
307.1441, found 307.1437. 
(S)-2-amino-3-(7-(E)-styryl-1H-indol-3-yl)propanoic acid (30) 
The above procedure afforded 9.8 mg (65% from 7-Br-tryptophan) of the 
desired product as a white solid.  
1H NMR (500 MHz, MeOD) δ 7.69 – 7.66 (m overlapped, 3H), 7.65 
(overlapped, 1H), 7.49 (d, J = 7.4 Hz, 1H), 7.39 (t, J = 7.7 Hz, 2H), 7.30 
(overlapped, 1H), 7.29 (overlapped, 1H), 7.27 (overlapped, 1H), 7.12 (t, J 
= 7.4 Hz, 1H), 3.90 (dd, J = 9.3, 4.1 Hz, 1H, CH), 3.55 (dd, J = 15.2, 4.1 
Hz, 1H, CHAHB), 3.20 (dd, J = 15.2, 9.3 Hz, 1H, CHAHB).13C NMR (126 
MHz, MeOD) δ 173.0 (CO), 137.9 (C), 135.0 (C), 128.5 (C), 128.3 (2CH), 
127.9 (C), 127.0 (CH), 126.1 (2CH), 124.1 (CH), 123.9 (CH), 121.5 (C), 
119.3 (CH), 118.3 (CH), 117.6 (CH), 108.7 (C), 55.3 (CH), 27.0 (CH2). 
HRMS (FTMS -p NSI) C19H17N2O2 [M - H]- calculated for 305.1296, found 
305.1292. 
(S)-2-amino-3-(5-(4-methylstyryl)-1H-indol-3-yl)propanoic acid (31) 
The above procedure afforded 9.9 mg (62% from 5-Br-tryptophan) of the 
desired product as a yellowish solid. LC-MS analysis indicated the 
presence of separable E and Z isomers (1:7). 
1H NMR (500 MHz, MeOD) δ 7.91 (s, 1H), 7.45 (d, J = 8.2 Hz, 2H), 7.43 
(dd, J = 8.6, 1.4 Hz, 1H), 7.37 (d, J = 8.6 Hz, 1H), 7.26 (d, J = 16.3 Hz, 
1H), 7.21 (s, 1H), 7.17 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 16.3 Hz, 1H), 3.91 
(dd, J = 9.7, 3.8 Hz, 1H), 3.57 (dd, J = 15.2, 3.8 Hz, 1H), 3.18 (dd, J = 
15.2, 9.7 Hz, 1H), 2.35 (s, 3H). 13C NMR (126 MHz, MeOD) δ 173.1 (CO), 
136.8 (C), 136.3 (C), 135.4 (C), 129.1 (C), 128.9 (CH), 128.9 (2CH), 
127.4 (C), 125.7 (2CH), 125.2 (CH), 124.4 (CH), 120.2 (CH), 116.6 (CH), 
111.3 (CH), 108.7 (C), 55.3 (CH), 27.2 (CH2), 19.9 (CH3). HRMS (FTMS 
+p ESI) m/z C20H21N2O2+ [M + H]+ calculated 321.1598, found 321.1595. 
 (S)-2-amino-3-(5-(4-aminostyryl)-1H-indol-3-yl)propanoic acid (33) 
The above procedure afforded 10.4 mg (65% from 5-Br-tryptophan) of 
the desired product as a yellowish solid. LC-MS analysis indicated the 
presence of separable E and Z isomers (2:1). 
1H NMR (500 MHz, MeOD) δ 7.61 (s, 1H, ArH), 7.34 (d, J = 8.5 Hz, 1H, 
ArH), 7.21 – 7.18 (m, 2H, ArH, CH=), 7.04 (d, J = 8.4 Hz, 2H, ArH), 6.74 
(d, J = 8.4 Hz, 1H, ArH), 6.58 (d, J = 12.1 Hz, 1H, =CH), 6.55 (d, J = 8.4 
Hz, 2H, ArH), 3.78 (dd, J = 9.6, 4.1 Hz, 1H, CH), 3.46 (dd, J = 15.1, 4.1 
Hz, 1H, CHAHB), 3.07 (dd, J = 15.1, 9.6 Hz, 1H, CHAHB). 13C NMR (126 
MHz, MeOD) δ 172.9 (CO), 146.6 (C-NH2), 136.1 (C), 129.6 (CH), 129.0 
(C), 128.0 (CH), 127.4 (C), 127.0 (C), 126.7 (CH), 125.7 (CH), 124.1 
(CH), 122.7 (CH), 118.5 (CH), 115.3 (CH), 114.7 (CH), 110.6 (CH), 108.5 
(C), 55.3 (CH), 27.0 (CH2). HRMS (FTMS +p ESI) m/z C19H20N3O2 [M + 
H]+ calculated 322.1550, found 322.1544. 
(S)-2-amino-3-(7-(4-aminostyryl)-1H-indol-3-yl)propanoic acid (34) 
The above procedure afforded 8.8 mg (55% from 7-Br-tryptophan) of the 
desired product as a yellowish solid. LC-MS analysis indicated the 
presence of separable E and Z isomers (8:1). 
 1H NMR (500 MHz, MeOD) δ 7.60 (t, J = 7.7 Hz, 1H, ArH), 7.40 (dd, J = 
8.4, 2.9 Hz, 2H, ArH), 7.33- - 7.28 (m, 1H, CH=), 7.18 – 7.01 (m, 2H, 
ArH), 7.01 – 6.90 (m, 1H, CH=), 6.73 (d, J = 8.4 Hz, 1H, ArH), 6.59 (s, 1H, 
ArH), 6.46 (d, J = 8.5 Hz, 1H, ArH), 3.87 (dt, J = 9.3, 3.4 Hz, 1H, CH), 
3.52 (dt, J = 14.9, 4.0 Hz, 1H, CHAHB), 3.15 (dt, J = 15.4, 9.1 Hz, 1H, 
CHAHB). 13C NMR (126 MHz, MeOD) δ 174.4 (CO), 148.7 (C-NH2), 148.5 
(C), 136.2 (C), 132.5 (CH), 131.0 (CH), 129.3 (C), 128.8 (C), 128.6 (CH), 
125.3 (CH), 123.7 (C), 122.7 (CH), 120.7 (CH), 120.1 (CH), 119.0 (CH), 
118.1 (CH), 116.5 (CH), 109.9 (C), 56.7 (CH), 28.5 (CH2). HRMS (FTMS 
+p ESI) m/z C19H20N3O2 [M + H]+ calculated 322.1550, found 322.1544. 
(S)-2-amino-3-(5-(4-fluorostyryl)-1H-indol-3-yl)propanoic acid (35) 
The above procedure afforded 14.6 mg (90% from 5-Br-tryptophan) of 
the desired product as a yellowish solid. LC-MS analysis indicated the 
presence of separable E and Z isomers (15:1). 
1H NMR (500 MHz, MeOD) δ 7.88 (s, 1H), 7.56 (dd, J = 8.7, 5.4 Hz, 2H), 
7.43 (dd, J = 8.5, 1.2 Hz, 1H), 7.36 (d, J = 8.5 Hz, 1H), 7.28 – 7.13 (m, 
3H), 7.07 (t, J = 8.8 Hz, 2H), 3.96 (dd, J = 9.2, 4.0 Hz, 1H, CH), 3.55 (dd, 
J = 15.1, 4.0 Hz, 1H, CHAHB), 3.20 (dd, J = 15.1, 9.2 Hz, 1H, CHAHB). 13C 
NMR (126 MHz, DMSO-d6) δ 170.5 (CO), 161.2 (d, JC-F = 248 Hz, CF), 
136.3 (C), 134.4 (C), 130.3 (CH), 127.7 (d, JC-F = 6.2 Hz, CH),), 125.2 
(CH), 123.7 (CH), 119.8 (CH), 117.5 (CH), 115.5 (d, JC-F = 21.2 Hz, CH), 
111.8 (CH), 109.4 (C), 54.2 (CH), 26.9 (CH2). 19F NMR (471 MHz, 
MeOD) δ -115.4 (major), -114.8 (minor) isomer. HRMS (FTMS +p ESI) 
m/z C19H18FN2O2 [M + H]+ calculated 325.1347, found 325.1337. 
(S)-2-amino-3-(7-((E)-4-fluorostyryl)-1H-indol-3-yl)propanoic acid 
(36)  
The above procedure afforded 12.9 mg (80% from 7-Br-tryptophan) of 
the desired product as a yellowish solid.  
1H NMR (500 MHz, MeOD) δ 7.68 – 7.65 (m overlapped, 3H), 7.58 (d, J 
= 16.3 Hz, 1H), 7.47 (d, J = 7.4 Hz, 1H), 7.29 (s, 1H), 7.27 (d, J = 16.3 Hz, 
1H), 7.14 – 7.10 (m, overlapped, 3H), 3.89 (dd, J = 9.3, 4.1 Hz, 1H, CH), 
3.55 (dd, J = 15.3, 4.1 Hz, 1H, CHAHB), 3.20 (dd, J = 15.3, 9.3 Hz, 1H, 
CHAHB). 13C NMR (126 MHz, MeOD) δ 173.0 (CO), 162.2 (d, JC-F = 245.8 
Hz, CF), 135.0 (C), 134.3 (C), 127.9 (C), 127.8 (d, JC-F = 7.9 Hz, CH), 
127.2 (CH), 124.1 (CH), 123.9 (CH), 121.4 (C), 119.3 (CH), 118.3 (CH), 
117.7 (CH), 115.1 (d, JC-F = 21.9 Hz, CH), 108.7 (C), 55.4 (CH), 27.0 
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(CH2). 19F NMR (471 MHz, MeOD) δ -117. HRMS (FTMS +p ESI) m/z 
C19H18FN2O2 [M + H]+ calculated 325.1347, found 325.1342. 
(S)-2-amino-3-(7-((E)-3-fluorostyryl)-1H-indol-3-yl)propanoic acid 
(37) 
The above procedure afforded 14.9 mg (92% from 7-Br-tryptophan) of 
the desired product as a white solid.  
1H NMR (500 MHz, MeOD) δ 7.73 – 7.62 (m, 2H), 7.49 (d, J = 7.4 Hz, 
1H), 7.45 – 7.33 (m, 3H), 7.26 (d, J = 17.0 Hz, 2H), 7.11 (t, J = 7.6 Hz, 
1H), 6.98 (td, J = 8.3, 1.9 Hz, 1H), 3.91 (dd, J = 9.1, 4.1 Hz, 1H, CH), 
3.53 (dd, J = 15.2, 4.1 Hz, 1H, CHAHB), 3.20 (dd, J = 15.2, 9.1 Hz, 1H, 
CHAHB). 13C NMR (126 MHz, MeOD) δ 174.2 (CO), 164.7 (d, JC-F = 242 
Hz, CF), 141.9 (d, JC-F = 8.8 Hz, C), 136.5 (C), 131.3 (d, JC-F = 8.8 Hz, 
CH), 129.4 (C), 128.3 (CH), 126.9 (CH), 125.6 (CH), 123.7 (CH), 122.4 
(C), 120.7 (CH), 119.9 (CH), 119.4 (CH), 114.9 (d, JC-F = 22 Hz, H-C-CF), 
113.4 (d, JC-F = 28 Hz, H-C-CF), 110.00 (C), 56.5 (CH), 28.3 (CH2). 19F 
NMR (377 MHz, DMSO-d6) δ -113.5. HRMS (FTMS +p ESI) m/z 
C19H18FN2O2 [M + H]+ calculated 325.1347, found 325.1338. 
(S)-2-amino-3-(5-((E)-4-cyanostyryl)-1H-indol-3-yl)propanoic acid 
(38) 
The above procedure afforded 15 mg (91% from 5-Br-tryptophan) of the 
desired product as a yellowish solid.  
1H NMR (500 MHz, MeOD) δ 7.96 (s, 1H, ArH), 7.77 – 7.61 (m, 4H, ArH, 
CH=), 7.60 – 7.44 (m, 2H, ArH), 7.39 (d, J = 8.5 Hz, 1H, ArH), 7.26 – 
7.13 (m, 2H, ArH), 3.93 (dd, J = 9.1, 4.1 Hz, 1H, CH), 3.54 (dd, J = 15.1, 
3.9 Hz, 1H, CHAHB), 3.21 (dd, J = 15.2, 9.1 Hz, 1H, CHAHB). 13C NMR 
(126 MHz, DMSO) δ 169.8 (CO), 142.8 (C), 136.7 (C), 134.4 (CH), 132.6 
(CH), 127.6 (C), 127.1 (C), 126.6 (CH), 125.1 (CH), 123.1 (CH), 120.1 
(CH), 119.3 (C), 118.5 (CH), 111.8 (CH), 110.4 (C), 108.5 (C), 54.7 (CH), 
27.1 (CH2). HRMS (FTMS -p NSI) C20H16N3O2 [M - H]- calculated for 
330.1248, found 330.1245. 
(S)-2-amino-3-(7-((E)-4-cyanostyryl)-1H-indol-3-yl)propanoic acid 
(39) 
The above procedure afforded 14.7 mg (89% from 7-Br-tryptophan) of 
the desired product as a yellowish solid 
1H NMR (500 MHz, MeOD) δ 7.86 – 7.75 (m, 3H, ArH), 7.74 – 7.65 (m, 
3H, ArH, CH=), 7.51 (d, J = 7.4 Hz, 1H, ArH), 7.31 (d, J = 16.1 Hz, 1H, 
CH=), 7.29 (s, 1H, ArH), 7.13 (t, J = 7.7 Hz, 1H, ArH), 3.98 (dd, J = 8.8, 
4.4 Hz, 1H, CH), 3.52 (dd, J = 15.3, 4.1 Hz, 1H, CHAHB), 3.23 (dd, J = 
15.3, 8.8 Hz, 1H, CHAHB). 13C NMR (126 MHz, MeOD) δ 173.6 (CO), 
144.2 (C), 136.5 (C), 133.6 (CH), 132.9 (CH), 130.7 (CH), 129.4 (CH), 
128.1 (CH), 127.8 (CH), 125.9 (CH), 122.1 (C), 120.8 (CH), 120.4 (CN), 
112.0 (CH), 111.2 (C), 109.8 (C), 55.7 (CH), 28.0 (CH2). HRMS (FTMS -
p NSI) C20H16N3O2 [M - H]- calculated for 330.1248, found 330.1245. 
(S)-2-amino-3-(5-(2-(pyridin-4-yl)vinyl)-1H-indol-3-yl)propanoic acid 
(40) 
The above procedure afforded 13 mg (85% from 5-Br-tryptophan) of the 
desired product as a reddish solid. LC-MS analysis indicated the 
presence of separable E and Z isomers (3:1). 
1H NMR (500 MHz, MeOD) δ 8.51 (d, J = 5.9 Hz, 2H, ArH), 7.86 (s, 1H, 
ArH), 7.66 (d, J = 16.4 Hz, 1H, CH=CH-Py), 7.56 (d, J = 5.5 Hz, 2H, ArH), 
7.47 (d, J = 8.5 Hz, 1H, ArH), 7.38 (d, J = 8.4 Hz, 1H, ArH), 7.23 (s, 1H, 
ArH), 7.13 (d, J = 16.4 Hz, 1H, CH=CH-Py), 3.91 (dd, J = 9.2, 3.6 Hz, 1H, 
CH), 3.56 (dd, J = 15.0, 3.6 Hz, 1H, CHAHB), 3.21 (dd, J = 15.0, 9.2 Hz, 
1H, CHAHB). 13C NMR (126 MHz, MeOD) δ 173.0 (CO), 146.9 (CH-N), 
131.1 (C), 129.6 (CH), 127.9 (C), 127.2 (CH), 126.8 (C), 123.8 (CH), 
122.1(C), 121.3 (CH), 119.3 (CH), 118.7 (CH), 116.9 (CH), 108.5 (C), 
55.3 (CH), 27.2 (CH2). HRMS (FTMS +p ESI) m/z C18H18N3O2 [M + H]+ 
calculated 308.1394, found 308.1388. 
(S)-2-amino-3-(7-((E)-2-(pyridin-4-yl)vinyl)-1H-indol-3-yl)propanoic 
acid (41) 
The above procedure afforded 10.9 mg (71% from 7-Br-tryptophan) of 
the desired product as a reddish solid.  
1H NMR (500 MHz, MeOD) δ 8.47 (d, J = 5.8 Hz, 2H, ArH), 7.95 (d, J = 
16.4 Hz, 1H, CH=CH-Py), 7.74 (d, J = 7.6 Hz, 1H, ArH), 7.64 (d, J = 6.1 
Hz, 2H, ArH), 7.54 (d, J = 7.4 Hz, 1H, ArH), 7.30 (s, 1H, ArH), 7.26 (d, J 
= 16.3 Hz, 1H, CH=CH-Py), 7.14 (t, J = 7.7 Hz, 1H, ArH), 3.88 (dd, J = 
9.1, 4.2 Hz, 1H, CH), 3.52 (dd, J = 15.3, 4.2 Hz, 1H, CHAHB), 3.20 (dd, J 
= 15.3, 9.1 Hz, 1H, CHAHB). 13C NMR (126 MHz, MeOD) δ 174.3 (CO), 
150.2 (2CH-N), 148.1 (C), 136.6 (C), 131.3 (CH=CH-Py), 129.6 (C), 
126.3 (CH=CH-Py), 125.8 (CH), 122.4 (2CH), 121.6 (C), 120.8 (CH), 
120.7 (CH), 120.6 (CH), 110.3 (C), 56.6 (CH), 28.3 (CH2). HRMS (FTMS 
+p ESI) m/z C18H18N3O2 [M + H]+ calculated 308.1394, found 308.1392. 
Barettin purification from extract[21] 
Barettin extract was kindly provided by Dr. Paco Cárdenas, Uppsala 
University, Sweden; 2g of freeze dried extract was added onto a filter 
paper in a funnel and rinsed copiously with Dichloromethane to remove 
any lipids from the sample. After rinsing with DCM, the freeze dried 
extract was washed thoroughly with 60% aqueous acetonitrile. The 
washings were checked via LCMS and combined. The sample was 
concentrated to ~1.5 mL.  
Barretin extract was purified via RP-HPLC using a Phenomenex Luna 
C18 (5micron, 250×21.2 mm) with UV detection at 234nm. The 
compound was eluted using a shallow linear gradient with starting 
conditions 95% solvent A (0.1% formic acid in MQ water) to 5% solvent B 
(ACN) to 40% solvent B over 40 mins. Over the next 15 mins solvent B 
was increased to 95%, held isocratically for 5 mins before returning to 
starting conditions. Barettin (8 mg) eluted with a retention time of 37 min 
and was confirmed by LCMS and characterised by NMR. 
(R)-1-(3-(5-(((Z)-6-bromo-1H-indol-3-yl)methylene)-3,6-
dioxopiperazin-2-yl)propyl)guanidine (42) 
1H NMR (700 MHz, MeOD) δ 7.75 (s, 1H, Ar-CH), 7.66 – 7.46 (m, 2H), 
7.24 (dd, 1H, J = 8.5, 1.7 Hz, Ar-CH), 7.17 (s, 1H, Ar-CH), 4.20 (t, 1H, J = 
5.6 Hz, CH), 3.23-3.19 (m, 2H, CH2), 1.99-1.93 (m, 1H, CHAHB) 1.92 – 1. 
85 (m, 1H, CHAHB), 1.77-1.66 (m, 2H, CH2). 13C NMR (176 MHz, MeOD) 
δ 167.2 (CO), 162.1 (CO), 157.2 (C(NH)2NH2), 137.0 (C), 126.2 (CH), 
126.1 (C), 123.2 (CH), 121.9 (CH), 119.5 (CH), 115.7 (C), 114.3 (CBr), 
109.7 (CH), 108.5 (C), 55.1 (CH), 40.5 (CH2), 31.2 (CH2), 23.7 (CH2). MS 
(ESI) m/z 421 (100) [M(81Br) + H]+, 419 (100) [M(79Br) + H]+; HRMS 
(FTMS +p ESI): m/z calculated for: C17H20BrN6O [M(79Br) + H]+: 
419.0826; found: 419.0809. 
Heck cross-coupling on purified Barettin in aqueous conditions 
giving 1-(3-((R)-5-(Z)-((6-(4-fluorostyryl)-1H-indol-3-yl)methylene)-
3,6-dioxopiperazin-2-yl)propyl)guanidine (43) 
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A stock solution of catalyst was prepared as follows: sodium 
tetrachloropalladate (1.5 mg, 5 µmol), TXPTS (7.0 mg, 11.5 µmol, 23 
mol%) were purged with argon and stirred at r.t. for 15 min after adding 1 
mL of degassed water/acetonitrile (1:1) mixture. Then, in a separate MW 
vial barretin (2 mg, 0.005 mmol) was added together with Na2CO3 (2 mg, 
0.02 mmol, 4 eq.) followed by addition of the 4-fluorostyrene (4 µl, 0.15 
mmol, 10 eq) and Pd-catalyst (10 mol% from stock). The vial was closed 
and the reaction mixture was stirred and heated at 90 °C (MW) for 2.5 
hours. LC-MS analysis showed full conversion. Purification was done via 
RP-HPLC using a Phenomenex Luna C18 (5 micron, 250×21.20 mm) 
with UV detection at 330 nm. The compound was eluted using a shallow 
linear gradient with starting conditions 95% solvent A (0.1% formic acid in 
MQ water) to 5% solvent B (ACN) to 40% solvent B over 40 mins. Over 
the next 15 mins solvent B was increased to 95%, held isocratically for 5 
mins before returning to starting conditions. Barettin-Heck derivative 
eluted with a retention time of 39 min and was confirmed by LCMS and 
1H NMR. Depicted product was obtained ~ 0.5 mg (21% isolated yield) as 
a white solid. 
1H NMR (700 MHz, MeOD) δ 7.81 (s, 1H, Ar-CH), 7.69 (d, 1H, J = 8.4 Hz, 
Ar-CH) 7.65 – 7.54 (m, 3H), 7.47 (d, 1H, J = 8.4 Hz, Ar-CH) 7.27 (s, 1H, 
Ar-CH), 7.19 (d, 1H, J = 16.3Hz, Ar-CH), 7.11 (t, 2H, J = 8.7 Hz, 2H) 4.25 
(t, 1H, J = 5.6 Hz, CH), 3.27-3.22 (m, 2H, CH2), 2.03-1.98 (m, 1H, 
CHAHB) 1.96 – 1. 89 (m, 1H, CHAHB), 1.82-1.70 (m, 2H, CH2). 19F NMR 
(659 MHz, MeOD) δ -77.1. MS (ESI) m/z 461.2 (100); HRMS (FTMS +p 
ESI): m/z calculated for C25H26FN6O2 [M + H]+:461.2096; found: 
461.2075. 
Culture conditions and isolation of pacidamycin D and Br-
pacidamycin D (44).8 
Starter cultures of engineered strain Streptomyces coelicolor RG1104, 
with prnA knock-in (performed as previously reported3) were obtained by 
inoculating 150 ml ISP2 medium with 0.3 ml spore suspension 
(approximately 106-107 cfu/mL final concentration) and culturing for 24-48 
hours at 28 °C, 220 rpm. Starter culture (20 ml) was then added to 0.5 L 
ISP2 and incubated with shaking at 28 °C for 7-8 days. Pacidamycins 
were extracted from the cell-free broth using 0.05 volumes of XAD-16 
resin. The resin was washed with 20 volumes of water and the extract 
was eluted with 10 volumes of methanol. The solvent was removed in 
vacuo. The crude extract was then purified by ion-exchange 
chromatography using a 5 ml HiTrapTM SP-FF column (GE Healthcare). 
After loading, the column was washed with 6 volumes 50 mM sodium 
acetate, pH 3.6. Pacidamycins were eluted with 50 mM sodium acetate in 
a stepwise gradient from pH 3.6 to pH 5.6. the appropriate pacidamycin-
containing fractions were combined and further purified on a Luna C18(2) 
250×22.10mm column, initial composition 10% acetonitrile 90 % RP 
buffer A, held for 2 mins before reaching 40% acetonitrile over 40 mins 
compound eluted at around 28 mins. Over the next 20 mins quick 
gradient up to 95% acetonitrile which was held for 5 mins before 
returning to starting conditions. 
Pacidamycin-D: 1H NMR (700 MHz, MeOD) δ 7.61 (d, J = 7.7 Hz, 1H), 
7.45 (d, J = 8.2 Hz, 1H), 7.31 (dd, J = 8.1, 1.8 Hz, 1H), 7.20 (s, 2H), 7.12 
– 7.09 (m, 1H), 5.98 (s, 1H), 5.88 (s, 1H), 5.76 (dd, J = 8.1, 1.9 Hz, 1H), 
4.52 (ddq, J = 8.6, 6.5, 2.1 Hz, 3H), 4.45 (dd, J = 9.3, 2.0 Hz, 1H), 4.25 
(qd, J = 7.0, 1.9 Hz, 1H), 3.28 – 3.16 (m, 2H), 2.79 (d, J = 1.9 Hz, 3H), 
2.59 (d, J = 17.8 Hz, 1H), 1.41 (dd, J = 7.1, 1.9 Hz, 1H), 1.29 (dd, J = 7.0, 
1.9 Hz, 3H), 1.22 (d, J = 7.2 Hz, 3H), 1.12 (dd, J = 6.9, 1.9 Hz, 3H). 
MS (ESI) m/z 712 (100) HRMS (FTMS +p ESI): m/z calculated for 
C32H42N9O10 [M + H]+ 712.3049; found: 712.3044. 
Br-Pacidamycin-D (44) 
Tabulated HSQC NMR data and comparison with wild type pacidamycin 
D is given in SI. MS (ESI): 790 (100) [M(79Br) + H]+, 792 (100) [M(81Br) + 
H]+; HRMS (FTMS +p ESI): m/z calculated for C32H41BrN9O10+ [M(79Br + 
H)]+: 790.2154; found: 790.2150. 
Heck cross-coupling of Br-pacidamycin D to give 45 
To a solution of the purified 7-Br-pacidamycin D (~0.5 mg) in degassed 
water-acetonitrile (3:1), sodium tetrachloropalladate (10 mol%), TXPTS 
(23 mol%) (from stock solution in degassed water-acetonitrile (3:1) 10 
mM) were added followed by Na2CO3 (4 eq.) and 4-fluorostyrene (5 eq) 
were added. The vial was closed and the reaction mixture was stirred 
and heated at 90 °C (MW) for 2 hour. After completion, the reaction was 
cooled down to rt was diluted with water (10 ml) and acidified (pH ~2-3) 
using 0.1 M HCl. The resulting mixture was extracted with ethyl acetate 
(3×10 mL). Complete conversion was observed by LC-HRMS analysis of 
the crude reaction mixture. Attempted purification by HPLC was not 
successful to isolate desired product, which may be due to very low 
quantities of product 45. 
MS (ESI): 832 (100) [M + H]+; HRMS (FTMS +p ESI): m/z calculated for 
C40H47FN9O10+ [M + H]+: 832.3424; found: 832.3422. 
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